




**Fig. S1. Systemic treatment choices for case 1 (moderate-to-severe head and neck dermatitis) of experts from (A) Denmark, (B) Norway, (C) Sweden and (D) Finland.** (A) Dermatologists from Denmark chose methotrexate as first-line, second-line was too diverse to summarize with a small sample and dupilumab as the third-line. (B) Dermatologists from Norway tended to choose cyclosporine as first-line, methotrexate as second-line and third-line was too diverse to summarize with a small sample. (C) Treatment choices made by dermatologists from Sweden were too diverse to summarize with a small sample size. (D) Dermatologists from Finland tended to choose methotrexate as first-line, second-line was too diverse to summarize with a small sample and all chose dupilumab as third-line.




**Fig. S2. Systemic treatment choices for case 2 (moderate-to-severe AD with type I allergies) of experts from (A) Denmark, (B) Norway, (C) Sweden and (D) Finland.** (A) Dermatologists from Denmark chose methotrexate as first-line, tended to choose azathioprine for second-line and all chose dupilumab for third-line. (B) Dermatologists from Norway tended to choose cyclosporine as first-line and the next steps were too diverse to summarize with a small sample. (C) Dermatologists from Sweden tended to choose cyclosporine as first-line and next steps were too diverse to summarize with a small sample. (D) Dermatologists from Finland tended to choose cyclosporine as first-line, second-line was too diverse to summarize with a small sample and they all chose dupilumab for third-line.




**Fig. S3. Systemic treatment choices for case 3 (moderate-to-severe AD with hand eczema) of experts from (A) Denmark, (B) Norway, (C) Sweden and (D) Finland.** (A) Dermatologists from Denmark chose methotrexate as first-line, azathioprine as second-line and third-line was too diverse to summarize with a small sample. (B) Dermatologists from Norway chose alitretinoin as first-line, tended to choose cyclosporine as second-line and third-line was too diverse to summarize with a small sample. (C) Treatment choices made by dermatologists from Sweden were too diverse to summarize with a small sample size. (D) Dermatologists from Finland chose cyclosporine as first-line, tended to choose azathioprine as second-line and methotrexate as third-line.



**Fig. S4. Systemic treatment choices for case 4 (moderate-to-severe AD with recurrent infections) of experts from (A) Denmark, (B) Norway, (C) Sweden and (D) Finland.** (A) Dermatologists from Denmark chose methotrexate for first-line treatment, either azathioprine or cyclosporine for the second-line and dupilumab for third-line. (B) Treatment choices made by dermatologists from Norway were too diverse to summarize with a small sample size. (C) Dermatologists from Sweden tended to choose methotrexate for first-line, dupilumab for the second-line and azathioprine for third-line. Mycophenolate mofetil was selected only by Swedish dermatologists. (D) Dermatologists from Finland tended to choose cyclosporine for first-line and chose dupilumab for third-line; second-line choices were too diverse to summarize.



**Fig. S5. Systemic treatment choices for case 5 (moderate-to-severe lichenified AD with severe itch) of experts from (A) Denmark, (B) Norway, (C) Sweden and (D) Finland.** (A) Dermatologists from Denmark tended to choose methotrexate as the first-line, azathioprine for second-line and all chose dupilumab for third-line. (B) Dermatologists from Norway chose cyclosporine as the first-line, tended to choose methotrexate for second-line and third-line steps were too diverse to summarize. (C) Treatment choices made by dermatologists from Sweden were too diverse to summarize with a small sample size. (D) Dermatologists from Finland tended to choose dupilumab in the first- and third-line, but the second-line choice was too diverse to summarize with a small sample.



**Fig. S6. Systemic treatment choices for case 6 (moderate-to-severe, late-onset AD) of experts from (A) Denmark, (B) Norway, (C) Sweden and (D) Finland.** (A) Dermatologists from Denmark tend to choose methotrexate for first-line, azathioprine as second-line and all chose dupilumab as third-line. (B) Dermatologists from Norway tend to choose cyclosporine for first-line, methotrexate for second-line and the choice of third-line was too diverse to summarize. (C) Dermatologists from Sweden chose methotrexate for first-line, tended to choose dupilumab for second-line and the third-line choice was too diverse to summarize. (D) Dermatologists from Finland tended to choose methotrexate for first- and second-line and all chose dupilumab for third-line.